Table 5.
Univariate Cox analysis for progression‐free survival
| Variable | HR (95% CI) | p value |
|---|---|---|
| Gender: Male vs. female | 1.3 (0.6–2.8) | .475 |
| Race: White vs. Black | 1.2 (0.6–2.3) | .686 |
| Age group: 50 to <65 vs. 18 < 50 years | 0.8 (0.4–1.9) | .628 |
| Age group: ≥65 vs. 18 to <50 years | 0.7 (0.3–1.7) | .448 |
| Tumor grade | ||
| G2 vs. G1 | 0.3 (0.1–1) | .059 |
| G3 vs. G1 | 0.2 (0–1) | .053 |
| Gx vs. G1 | 0.4 (0.1–1.4) | .147 |
| KRAS: Mutated vs. wild type | 1.9 (1–3.8) | .058 |
| BRAF: Unknown vs. wild type | 0.8 (0.4–1.6) | .506 |
| MSI: Stable vs. low | 1 (0.1–7.5) | .966 |
| PI3K: Mutated vs. wild type | 0.8 (0.1–8.5) | .829 |
| Number of lines of therapy: ≥3 lines vs. <3 lines | 0.5 (0.2–1.2) | .145 |
| Prior treatment with bevacizumab: Yes vs. no | 1.4 (0.6–3.1) | .381 |
| Prior treated with cetuximab or panitumumab: Yes vs. no | 0.6 (0.3–1.2) | .131 |
| Prior treatment with capecitabine: Yes vs. no | 1.1 (0.6–2.1) | .788 |
| Hypertension: Yes vs. no | 0.9 (0.4–1.8) | .698 |
Abbreviations: BRAF, B‐Raf; CI, confidence interval; G1, grade 1; G2, grade 2; G3, grade 3; Gx, grade not assessed; HR, hazard ratio; KRAS, K‐ras; MSI, microsatellite instability.